Eurocept buys Medizorg and tries to re-invent homecare

Eurocept, the Dutch pharmaceutical and home care company backed by private equity house GIMV, is to buy medicalised homecare group Medizorg to create a group with sales of €300m with Benelux and Pan-Nordic ambitions. We talk to Eurocept CEO, Mike van Woensel about homecare business models.

We would welcome your thoughts on this story. Email your views to Max Hotopf or call 0207 183 3779.

Article Tags

Results (534) from

HBI Market Reports

Belgium

Denmark

Finland

Medicalised Homecare

Netherlands

Norway

Sweden

Our Services

Company

Resources

Our Services

Company

Resources

Find Us

Please wait while your search results are being generated.

Get a CLEAR picture on private healthcare services across Europe

Subscribe now to Healthcare Europa and get instant access to:

check

check

check

check

check

check

check

check

Know the pulse of the market from just £1040.

Get a CLEAR picture on private healthcare services across Emerging Markets

Subscribe now to Healthcare Nova and get instant access to:

check

check

check

check

check

check

check

check

Know the pulse of the market from just £1040.

Get a CLEAR picture of ALL the top players in 22 sectors across 34 countries

Subscribe now to the only database of the Top 1,700 operators in Europe. Use it to:

check

check

check

check

check

Instant access plus ongoing updatesfrom £1,895.

Get a CLEAR picture of the Top 1,300 players in Emerging Markets

Subscribe now to the only database of the Top 1,300 private healthcare operators in Emerging Markets . Use it to:

check

check

check

check

check

check

Instant access plus ongoing updatesfrom £1,895.

Know the pulse of the market
from just £1040.

Know the pulse of the market
from just £1040.

Subscribe now to the only database of the
Top 1,700 operators in Europe. Use it to:

Instant access plus ongoing updates
from £1,895.

Subscribe now to the only database of the Top 1,300 private
healthcare operators in Emerging Markets . Use it to:

Instant access plus ongoing updates
from £1,895.